共 139 条
[1]
Shah P(2018)Economic evaluation of the PCSK9 inhibitors in prevention of the cardiovascular diseases Curr Cardiol Rep 20 51-1210
[2]
Naghavi M(2017)Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet 390 1151-320
[3]
Abajobir AA(2016)Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States Clin Cardiol 39 313-687
[4]
Abbafati C(2015)Alirocumab: targeting PCSK9 to treat hypercholesterolemia Drugs Today (Barc) 51 681-933
[5]
Abbas KM(2018)Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER Circulation 118 034309-171
[6]
Abd-Allah F(2003)The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proc Natl Acad Sci 100 928-754
[7]
Abera SF(2016)Nonstatins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: role in non-familial hypercholesterolemia Prog Cardiovasc Dis 59 165-154
[8]
Aboyans V(2018)Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events Am J Health Syst Pharm 75 747-1509
[9]
Adetokunboh O(2018)Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease Int J Cardiol 253 148-1722
[10]
Afshin A(2015)Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 372 1500-24